MANKIND2,246.00

Mankind Pharma Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLATORNTPHARMLAURUSLABSBIOCONALKEMLUPINGLENMARKMcap ₹92,715 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation398.3621.2886.2
+ Finance Costs33.0404.0639.3
+ Interest Income-40.1-67.9-58.1
+ Dividend Income-0.00.00.0
+ Share-based Payments23.226.618.2
+ Unrealised FX (Gain) / Loss-3.6-2.4-32.0
+ Other Non-cash Items0.0-359.1-165.4
+ Other Reconciling Items-183.40.00.0
Changes in Working Capital
+ Inventories-55.0-220.7-50.8
+ Trade Receivables — Current-289.9-123.6-172.0
+ Other Financial Assets — Current113.328.2-12.6
+ Other Current Assets5.2-125.4-148.8
+ Trade Payables — Current97.5-146.0210.3
+ Other Financial Liabilities — Current2.7160.356.5
+ Other Current Liabilities50.9106.5-21.0
+ Provisions — Current95.7174.3243.1
Cash from Operating Activities
Profit Before Tax (per I/S)2,384.12,504.12,321.02,549.2
+ Total Adjustments (incl. Working Capital)247.8476.01,393.0
Cash from Operations (pre-tax)2,632.02,980.13,714.0
+ Income Taxes Paid479.5566.8592.7
Cash from Operating Activities2,152.42,413.43,121.3
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)315.3460.8626.0
+ Acq of Intangible Assets67.059.3111.3
+ Disp of Fixed Assets7.512.03.0
+ Disp of Investment Property0.08.00.0
+ Disp of Interests in Joint Ventures7.40.00.0
+ Share of Profits — Partnership Firms / LLPs0.00.07.8
+ Loans & Advances Made1.21.10.4
+ Dividends Received — Investing0.00.00.0
+ Interest Received — Investing40.167.958.1
+ Other Inflows / (Outflows) — Investing-1,753.1-12,249.6472.4
Cash from Investing Activities-2,081.7-12,683.0-196.4
Cash from Financing Activities
+ Proceeds from Issue of Shares0.02,963.221.5
+ Proceeds from Borrowings400.712,451.33,978.0
+ Repayment of Borrowings366.75,073.16,218.0
+ Payment of Lease Liabilities0.012.229.3
+ Payment of Finance Lease Liabilities3.3
+ Interest Paid25.496.7663.6
+ Dividends Paid0.00.041.3
+ Other Inflows / (Outflows) — Financing0.057.60.0
Cash from Financing Activities5.310,290.1-2,952.7
Net Changes in Cash (pre-FX)76.020.6-27.8
+ Effect of FX Rate Changes on Cash1.21.315.6
Net Changes in Cash77.221.9-12.2
Closing Cash382.0391.7
Reference Items
EBITDA2,535.13,017.93,617.43,826.8
EBITDA Margin %24.5324.7225.3425.97
Free Cash Flow (CFO − Capex)1,770.11,893.32,384.12,384.1
Free Cash Flow to Equity10,100.8-479.5
Free Cash Flow per Basic Share42.8845.8657.7557.75
Price to Free Cash Flow38.89
Cash Flow to Net Income1.111.201.61
Cash Paid for Taxes479.5566.8592.7
Cash Paid for Interest25.496.7663.6
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.